China Jo-Jo Drugstores, Inc. (CJJD)
USD 1.82
(0.91%)
USD 1.82
(0.91%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -4.23 Million USD | 79.97% |
| 2023 | -21.13 Million USD | -560.92% |
| 2022 | -3.19 Million USD | 61.81% |
| 2021 | -8.37 Million USD | -29.7% |
| 2020 | -6.45 Million USD | -390.05% |
| 2019 | -1.31 Million USD | 92.28% |
| 2018 | -17.05 Million USD | -202.26% |
| 2017 | -5.64 Million USD | -1362.24% |
| 2016 | 447.15 Thousand USD | -47.8% |
| 2015 | 856.55 Thousand USD | 103.38% |
| 2014 | -25.35 Million USD | -76.9% |
| 2013 | -14.33 Million USD | -276.05% |
| 2012 | 8.14 Million USD | -3.45% |
| 2011 | 8.43 Million USD | -14.14% |
| 2010 | 9.82 Million USD | 34264.95% |
| 2009 | -28.74 Thousand USD | -669.28% |
| 2008 | -3737.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -1.65 Million USD | 0.0% |
| 2024 Q2 | -462.12 Thousand USD | 0.0% |
| 2024 FY | -4.23 Million USD | 79.97% |
| 2024 Q3 | -1.65 Million USD | -258.13% |
| 2024 Q1 | -462.12 Thousand USD | 95.5% |
| 2023 Q2 | -297.39 Thousand USD | 0.0% |
| 2023 Q1 | -297.39 Thousand USD | 89.85% |
| 2023 Q3 | -10.27 Million USD | -3354.0% |
| 2023 Q4 | -10.27 Million USD | 0.0% |
| 2023 FY | -21.13 Million USD | -560.92% |
| 2022 Q2 | -262.74 Thousand USD | -100.0% |
| 2022 Q3 | -1.46 Million USD | -457.46% |
| 2022 Q4 | -2.92 Million USD | -100.0% |
| 2022 Q1 | -131.37 Thousand USD | 20.99% |
| 2022 FY | -3.19 Million USD | 61.81% |
| 2021 FY | -8.37 Million USD | -29.7% |
| 2021 Q1 | -388.59 Thousand USD | 86.98% |
| 2021 Q3 | -6.29 Million USD | -312.1% |
| 2021 Q4 | -166.27 Thousand USD | 97.36% |
| 2021 Q2 | -1.52 Million USD | -293.01% |
| 2020 FY | -6.45 Million USD | -390.05% |
| 2020 Q4 | -2.98 Million USD | -661.36% |
| 2020 Q3 | 531.78 Thousand USD | 143.41% |
| 2020 Q2 | -1.22 Million USD | 42.62% |
| 2020 Q1 | -2.13 Million USD | -159.64% |
| 2019 Q4 | 3.58 Million USD | 313.32% |
| 2019 Q2 | -1.58 Million USD | -145.79% |
| 2019 FY | -1.31 Million USD | 92.28% |
| 2019 Q3 | -1.67 Million USD | -5.72% |
| 2019 Q1 | -645.85 Thousand USD | 94.97% |
| 2018 Q2 | -1.16 Million USD | 17.66% |
| 2018 FY | -17.05 Million USD | -202.26% |
| 2018 Q1 | -1.41 Million USD | 71.83% |
| 2018 Q3 | -1.62 Million USD | -39.11% |
| 2018 Q4 | -12.84 Million USD | -690.13% |
| 2017 Q3 | -834.8 Thousand USD | -952.97% |
| 2017 FY | -5.64 Million USD | -1362.24% |
| 2017 Q4 | -5.03 Million USD | -503.54% |
| 2017 Q2 | 97.87 Thousand USD | -25.38% |
| 2017 Q1 | 131.15 Thousand USD | -83.67% |
| 2016 Q4 | 802.89 Thousand USD | 230.02% |
| 2016 Q2 | 151.17 Thousand USD | 36.67% |
| 2016 Q3 | -617.52 Thousand USD | -508.49% |
| 2016 FY | 447.15 Thousand USD | -47.8% |
| 2016 Q1 | 110.61 Thousand USD | -90.06% |
| 2015 Q4 | 1.11 Million USD | 779.54% |
| 2015 Q2 | -36.19 Thousand USD | 89.56% |
| 2015 Q1 | -346.73 Thousand USD | 97.73% |
| 2015 FY | 856.55 Thousand USD | 103.38% |
| 2015 Q3 | 126.53 Thousand USD | 449.62% |
| 2014 Q2 | -546.06 Thousand USD | 30.66% |
| 2014 Q3 | -8.73 Million USD | -1499.68% |
| 2014 Q4 | -15.28 Million USD | -75.01% |
| 2014 Q1 | -787.51 Thousand USD | 92.01% |
| 2014 FY | -25.35 Million USD | -76.9% |
| 2013 Q2 | -1.52 Million USD | -385.75% |
| 2013 Q4 | -9.85 Million USD | -182.62% |
| 2013 Q3 | -3.48 Million USD | -128.11% |
| 2013 Q1 | 534.88 Thousand USD | -68.37% |
| 2013 FY | -14.33 Million USD | -276.05% |
| 2012 Q4 | 1.69 Million USD | 7.45% |
| 2012 FY | 8.14 Million USD | -3.45% |
| 2012 Q3 | 1.57 Million USD | -3.66% |
| 2012 Q2 | 1.63 Million USD | -49.62% |
| 2012 Q1 | 3.24 Million USD | 34.27% |
| 2011 Q1 | 2.15 Million USD | -44.42% |
| 2011 Q4 | 2.41 Million USD | 7.94% |
| 2011 Q3 | 2.23 Million USD | 37.48% |
| 2011 FY | 8.43 Million USD | -14.14% |
| 2011 Q2 | 1.62 Million USD | -24.39% |
| 2010 FY | 9.82 Million USD | 34264.95% |
| 2010 Q4 | 3.87 Million USD | 46.34% |
| 2010 Q2 | 1.7 Million USD | 144640.53% |
| 2010 Q3 | 2.64 Million USD | 55.34% |
| 2010 Q1 | 1177.00 USD | 127.62% |
| 2009 Q4 | -4261.00 USD | 22.37% |
| 2009 Q1 | -4001.00 USD | 76.2% |
| 2009 Q3 | -5489.00 USD | -380.23% |
| 2009 FY | -28.74 Thousand USD | -669.28% |
| 2009 Q2 | -1143.00 USD | 71.43% |
| 2008 Q2 | -859.00 USD | 0.0% |
| 2008 Q4 | -16.8 Thousand USD | -137.45% |
| 2008 FY | -3737.00 USD | 0.0% |
| 2008 Q3 | -7079.00 USD | -724.1% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -19.93 Million USD | 78.76% |
| BIMI International Medical Inc. | -22.35 Million USD | 81.057% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | -24.41 Million USD | 82.654% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | -24.41 Million USD | 82.654% |
| Leafly Holdings, Inc. | -9.49 Million USD | 55.42% |
| Leafly Holdings, Inc. | -9.49 Million USD | 55.42% |
| LifeMD, Inc. | -20.59 Million USD | 79.441% |
| LifeMD, Inc. | -20.59 Million USD | 79.441% |
| TRxADE HEALTH, Inc. | -17.84 Million USD | 76.27% |
| PetMed Express, Inc. | -7.46 Million USD | 43.271% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.951% |